Rhythm Pharmaceuticals Announces $150M Public Offering of Common Stock

Rhythm Pharmaceuticals has announced a proposed public offering of $150 million of its common stock, with an option to purchase up to an additional $22.5 million. The offering is subject to market and other customary closing conditions, and there is no assurance as to whether or when the offering may be completed. Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.